{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T19:14:39Z","timestamp":1789413279110,"version":"build-2803163510"},"reference-count":36,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2026]]},"DOI":"10.3960\/jslrt.25056","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:08:12Z","timestamp":1769638092000},"page":"37-44","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of venetoclax combined with azacitidine for advanced blastic plasmacytoid dendritic cell neoplasm: experience from two Japanese cases"],"prefix":"10.3960","volume":"66","author":[{"given":"Asuka","family":"Shibamiya","sequence":"first","affiliation":[{"name":"Department of Hematology, International University of Health and Welfare Narita Hospital, Narita, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikako","family":"Ohwada","sequence":"additional","affiliation":[{"name":"Department of Hematology, International University of Health and Welfare Narita Hospital, Narita, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Tsutsui","sequence":"additional","affiliation":[{"name":"Department of Hematology, International University of Health and Welfare Narita Hospital, Narita, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akane","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, International University of Health and Welfare Narita Hospital, Narita, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Hematology, International University of Health and Welfare Narita Hospital, Narita, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Akatsuka","sequence":"additional","affiliation":[{"name":"Department of Dermatology, International University of Health and Welfare Narita Hospital, Narita, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihisa","family":"Hamada","sequence":"additional","affiliation":[{"name":"Department of Dermatology, International University of Health and Welfare Narita Hospital, Narita, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Sugaya","sequence":"additional","affiliation":[{"name":"Department of Dermatology, International University of Health and Welfare Narita Hospital, Narita, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, International University of Health and Welfare Narita Hospital, Narita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Shiomi","sequence":"additional","affiliation":[{"name":"Department of Anatomic Pathology, International University of Health and Welfare Narita Hospital, Narita, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiaki","family":"Nakaseko","sequence":"additional","affiliation":[{"name":"Department of Hematology, International University of Health and Welfare Narita Hospital, Narita, Japan,"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Fernandes F, Barreira R, Cortez J, Silveira M, Bain BJ. The distinctive cytology and disease evolution of blastic plasmacytoid dendritic cell neoplasm. Am J Hematol. 2018; 93: 1431-1432.","DOI":"10.1002\/ajh.25219"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Shumilov E, Mazzeo P, Ghandili S <i>et al.<\/i> Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations. Ann Hematol. 2024; 103: 1587-1599.","DOI":"10.1007\/s00277-023-05587-7"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Jain A, Sweet K. Blastic Plasmacytoid Dendritic Cell Neoplasm. J Natl Compr Canc Netw. 2023; 21: 515-521.","DOI":"10.6004\/jnccn.2023.7026"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Gangat N, Konopleva M, Patnaik MM <i>et al.<\/i> Venetoclax and hypomethylating agents in older\/unfit patients with blastic plasmacytoid dendritic cell neoplasm. Am J Hematol. 2022; 97: E62-E67.","DOI":"10.1002\/ajh.26417"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Sasaki Y, Murai S, Shiozawa E, Yamochi T, Hattori N. Blastic Plasmacytoid Dendritic Cell Neoplasm in Long-Term Complete Remission After Venetoclax Monotherapy. Cureus. 2024; 16: e52446.","DOI":"10.7759\/cureus.52446"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Wang Q, Zhao Y, Zang X <i>et al.<\/i> Low-dose venetoclax combined with azacitidine for blastic plasmacytoid dendritic cell neoplasm: a case report and literature review. Ann Hematol. 2024; 103: 999-1005.","DOI":"10.1007\/s00277-024-05633-y"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Le Calloch R, Arnaud B, Le Clech L <i>et al.<\/i> Achievement of rapid complete remission in an 87-year-old female patient with azacytidine-venetoclax for blastic plasmacytoid dendritic cell neoplasm. Ann Hematol. 2022; 101: 1347-1349.","DOI":"10.1007\/s00277-021-04718-2"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Nagate Y, Nakaya A, Kamimura R <i>et al.<\/i> Venetoclax Combined with Azacytidine Can Be a First-line Treatment Option for Elderly Blastic Plasmacytoid Dendritic Cell Neoplasm. Intern Med. 2023; 62: 2547-2551.","DOI":"10.2169\/internalmedicine.0318-22"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Khoury JD, Solary E, Abla O, <i>et al.<\/i> The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022; 36: 1703-1719.","DOI":"10.1038\/s41375-022-01613-1"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Garnache-Ottou F, Feuillard J, Ferrand C <i>et al.<\/i> Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia. Br J Haematol. 2009; 145: 624-636.","DOI":"10.1111\/j.1365-2141.2009.07679.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Mart\u00edn-Mart\u00edn L, L\u00f3pez A, Vidriales B <i>et al.<\/i> Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile. Oncotarget. 2015; 6: 19204-19216.","DOI":"10.18632\/oncotarget.4146"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Sakamoto K, Katayama R, Asaka R <i>et al.<\/i> Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response. Leukemia. 2018; 32: 2590-2603.","DOI":"10.1038\/s41375-018-0154-5"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Sakamoto K, Takeuchi K. Diagnostic approach to blastic plasmacytoid dendritic cell neoplasm: historical perspectives and current understanding. J Clin Exp Hematop. 2025; 65: 1-16.","DOI":"10.3960\/jslrt.24069"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Wang Y, Xiao L, Yin L <i>et al.<\/i> Diagnosis, treatment, and genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A review. Medicine (Baltimore). 2023; 102: e32904.","DOI":"10.1097\/MD.0000000000032904"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Pagano L, Valentini CG, Pulsoni A <i>et al.<\/i> Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013; 98: 239-246.","DOI":"10.3324\/haematol.2012.072645"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Yun S, Chan O, Kerr D <i>et al.<\/i> Survival outcomes in blastic plasmacytoid dendritic cell neoplasm by first-line treatment and stem cell transplant. Blood Adv. 2020; 4: 3435-3442.","DOI":"10.1182\/bloodadvances.2020001875"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Economides MP, Konopleva M, Pemmaraju N. Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm. Ther Adv Hematol. 2019; 10: 2040620719874733.","DOI":"10.1177\/2040620719874733"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Zhang Y, Sokol L. Clinical Insights into the Management of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancer Manag Res. 2022; 14: 2107-2117.","DOI":"10.2147\/CMAR.S330398"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Montero J, Stephansky J, Cai T <i>et al.<\/i> Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discov. 2017; 7: 156-164.","DOI":"10.1158\/2159-8290.CD-16-0999"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Pemmaraju N, Lane AA, Sweet KL <i>et al.<\/i> Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med. 2019; 380: 1628-1637.","DOI":"10.1056\/NEJMoa1815105"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Pemmaraju N, Sweet KL, Stein AS <i>et al.<\/i> Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. J Clin Oncol. 2022; 40: 3032-3036.","DOI":"10.1200\/JCO.22.00034"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 DiNardo CD, Rausch CR, Benton C <i>et al.<\/i> Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018; 93: 401-407.","DOI":"10.1002\/ajh.25000"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Azad F, Zhang J, Miranda CJ, Gravina M. Venetoclax and Azacitidine in the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm Refractory to Conventional Therapy. Cureus. 2022; 14: e33109.","DOI":"10.7759\/cureus.33109"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Nasiri A, Lami A, Alhumaidi A <i>et al.<\/i> Blastic Plasmacytoid Dendritic Cell Neoplasm: A Case Report. Cureus. 2023; 15: e37016.","DOI":"10.7759\/cureus.37016"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Tokioka R, Saito-Sasaki N, Sawada Y. A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm on the Chest. Cureus. 2024; 16: e70288.","DOI":"10.7759\/cureus.70288"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Wang X, Guo J, Liu Y <i>et al.<\/i> Venetoclax combined with azacitidine in blastic plasmacytoid dendritic cell neoplasm: a case report and comprehensive review on the current and future treatment. Front Med (Lausanne). 2024; 11: 1425833.","DOI":"10.3389\/fmed.2024.1425833"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Pemmaraju N, Phan LH, Fell G <i>et al.<\/i> Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN. Blood Neoplasia. 2025; 2: 100086.","DOI":"10.1016\/j.bneo.2025.100086"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Grushchak S, Joy C, Gray A <i>et al.<\/i> Novel treatment of blastic plasmacytoid dendritic cell neoplasm: A case report. Medicine (Baltimore). 2017; 96: e9452.","DOI":"10.1097\/MD.0000000000009452"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Schwede M, Tan IT, Atibalentja DF <i>et al.<\/i> Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm. Ann Hematol. 2020; 99: 2973-2975.","DOI":"10.1007\/s00277-020-04276-z"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Shah AM, Pereira D, Poveda J, Wang TP. Venetoclax monotherapy as front-line therapy for blastic plasmacytoid dendritic cell neoplasm. Leuk Res Rep. 2023; 20: 100380.","DOI":"10.1016\/j.lrr.2023.100380"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Albiol N, Novelli S, Mozos A <i>et al.<\/i> Venetoclax in relapsed\/refractory blastic plasmacytoid dendritic cell neoplasm with central nervous system involvement: a case report and review of the literature. J Med Case Rep. 2021; 15: 326.","DOI":"10.1186\/s13256-021-02939-7"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Adimora IJ, Wilson NR, Pemmaraju N. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics. Cancer. 2022; 128: 3019-3026.","DOI":"10.1002\/cncr.34345"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Oza N, Rathnam K, Sumeet G <i>et al.<\/i> Blastic Plasmacytoid Dendritic Cell Neoplasm: A Rare Case Report with Literature Review. Indian J Med Paediatr Oncol. 2021; 42: 496-500.","DOI":"10.1055\/s-0041-1736432"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Sastow D, Levavi H, Wagner N, Pratz K, Tremblay D. Ven the dose matters: Venetoclax dosing in the frontline treatment of AML. Blood Rev. 2024; 68: 101238.","DOI":"10.1016\/j.blre.2024.101238"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Fleischmann M, Jentzsch M, Brioli A <i>et al.<\/i> Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia. Ann Hematol. 2025; 104: 285-294.","DOI":"10.1007\/s00277-024-06048-5"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Cui J, Chen X, Li C, Yan Q, Yuan G. Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia. Hematology. 2024; 29: 2293512.","DOI":"10.1080\/16078454.2023.2293512"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/66\/1\/66_25056\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T04:31:01Z","timestamp":1775277061000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/66\/1\/66_25056\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.25056","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"25056"}}